The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2–selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. Here, BCL2 is linked to acute myeloid leukemia.